Actinium Pharmaceuticals, Inc. (ATNM) is a biopharmaceutical company focused on developing and commercializing targeted treatments for cancer using its proprietary technology platform. Based in New York, the company was founded in 2000 and focuses its operations on precision cancer medicine that seeks to leverage the body's own immune system to fight malignant cells.
Actinium's innovative Radiolabeled Antibody Technology employs Antibody Radiation Conjugates (ARCs), which allow for targeted delivery of a radioactive isotope, Actinium-225, directly to cancer cells, delivering the cell-killing power of radiation without the widespread damage to healthy tissue associated with standard radiation treatments. This precision approach potentially results in better efficacy, fewer side effects, and improved patient outcomes.
The company’s product line includes Iomab-B and Actimab-A. Iomab-B is an experimental treatment used in Bone Marrow Transplant (BMT), while Actimab-A is used in the treatment of Acute Myeloid Leukemia (AML).
Actinium Pharmaceuticals is actively involved in several ongoing clinical trials for both of these products and has a robust research and development pipeline, with several other therapeutic candidates in various stages of development aimed at solid and blood borne cancers.
The company also partners with other pharmacological and research institutions to continue to innovate and move the field of targeted cancer therapy forward. Actinium Pharmaceuticals, Inc. collaborates with world renowned cancer centers such as the Fred Hutchinson Cancer Research Center and the Memorial Sloan Kettering Cancer Center, underscoring its commitment to pursuing partnerships with leaders in the healthcare and pharmaceutical industry.
Actinium Pharmaceuticals, Inc. is publicly traded on the New York Stock Exchange under the ticker symbol "ATNM". The company has a dedicated team of professionals led by senior executives with extensive experience in the pharma and biotech industries.
In conclusion, Actinium Pharmaceuticals, Inc. is a key player in the emergent field of targeted cancer therapy. With their impressive portfolio of innovative products and ongoing research and development, they represent a beacon of hope for countless patients battling various forms of cancer.